|Chemical and physical data|
|Molar mass||522.586 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Remogliflozin etabonate (INN/USAN) is a proposed drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin is being developed by Avolynt, Inc.
Remogliflozin etabonate (RE) was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels. Remogliflozin etabonate has been studied at doses up to 1000 mg. A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated.
Method of action
Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.
- Statement on a nonproprietory name adopted by the USAN council
- Yahoo Finance http://finance.yahoo.com/news/avolynt-announces-completion-phase-2b-143600142.html. Missing or empty
- "Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.". 35. Nov 2012: 2198–200. doi:10.2337/dc12-0508. PMID 23011728.
- "Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.". 14. Jan 2012: 15–22. doi:10.1111/j.1463-1326.2011.01462.x. PMID 21733056.
- "Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.". Diabetes Obes Metab. 17: 94–7. Jan 2015. doi:10.1111/dom.12391. PMID 25223369.
- "Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.". 17. Jan 2015: 98–101. doi:10.1111/dom.12393. PMID 25238025.
- Prous Science: Molecule of the Month November 2007 Archived January 6, 2008, at the Wayback Machine.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|